Piper Sandler Companies , a leading investment bank, is pleased to announce the addition of Christian Draisbach as a managing director to the healthcare investment banking team. Draisbach will be responsible for advising and supporting clients in the biopharma sector.
Health Technology Insights: Bioconcrete Market to Reach $177.5 Billion by 2030 with Self-Healing Tech
“We are excited for Christian to join our healthcare investment banking team. Christian brings 20 years of experience advising biopharma executives and boards through the lifecycle of their business on complex strategic initiatives and mergers, acquisitions, divestitures and partnership transactions in the U.S., Europe and Asia. During his career, Christian has advised on some of the most relevant strategic transactions in the biopharma sector globally. His transaction experience spans the spectrum from early development-stage private transactions to some of the largest and highest-profile public deals. Adding Christian’s experience and network of relationships to our existing platform will drive the Piper Sandler biopharma M&A business both in the U.S. and abroad,” said Peter Day, managing director and global group head of healthcare investment banking at Piper Sandler.
Health Technology Insights: Inspira Health Appoints New Leaders and Trustees to its Network and Hospital Boards
Draisbach joins the firm from Centerview Partners where he was a managing director primarily focused on clients in the life sciences and broader healthcare sectors. Earlier in his career, Mr. Draisbach worked at Morgan Stanley in the mergers and acquisitions and financial sponsor coverage groups based in the U.S., Europe and Asia. Draisbach earned a M.Sc. in finance from the London School of Economics & Political Science (U.K.) and a B.A. in business administration from the University of St. Gallen (Switzerland).
“Piper Sandler has a well-earned reputation as a leading investment banking advisory firm in the healthcare sector and I’m excited to join at this pivotal inflection point in its growth strategy. Being at the forefront of providing intellectually rigorous and independent strategic advice, the firm has a long track record of building some of the most successful client-centric practices anchored in deep industry expertise. I look forward to working alongside this talented team and to build on its success serving clients in the biopharma sector in the U.S. and internationally,” said Draisbach.
Health Technology Insights: CDSS Market Growth: $1.9 Billion in 2023 to $3.1 Billion by 2030
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – businesswire
